Findings

What do systematic reviews say?

6 questions · 6 findings · 4 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 16.7%Very low 3 · 50%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%

Infliximab vs placebo

Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.6 [0.36, 1]
1 study · 282 participants
Very low

Vedolizumab vs placebo

Serious adverse events (6–10 weeks) · people with Crohn's disease

Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.91 [0.62, 1.33]
4 studies · 1126 participants
Low

Vedolizumab vs placebo

Serious adverse events (52–60 weeks) · people with Crohn's disease

Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.98 [0.68, 1.39]
3 studies · 894 participants
Low

Probiotics vs placebo

Serious adverse events (48 to 52 weeks) · Patients with quiescent ulcerative colitis

1 finding from 1 review

Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 351 participants
GRADE not reported

IM erythropoietin + IV iron sucrose vs IV iron sucrose + IM placebo

Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Oral ferric maltol vs oral placebo

Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients

It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 1 [0.15, 6.88]
1 study · 128 participants
Very low